BioNova Announces Swiftsure Innovations as the Winner of the Tenth Annual BioInnovation Challenge (BIC) at BioPort 2020
Halifax, NS – November 4, 2020 – Today Swiftsure Innovations from Newfoundland was named the winner of BioNova’s tenth annual BioInnovation Challenge (BIC) business pitch competition at BioPort 2020. Swiftsure is developing a novel endotracheal tube that will revolutionize oral care for mechanically ventilated patients.
“The BioInnovation Challenge gave us the opportunity to really hone our business plan and strategy,” Deanne McCarthy (RN), CEO & Founder said, “We have benefited not only from winning, but from the program and training it provided as a whole. It was also a great chance to learn about the game changing technologies being developed right here in Atlantic Canada.”
The eight semi-finalist startups from across Atlantic Canada that participated this year raised over $1 Million dollars since the start of 2020, making this one of the most competitive years in the competitions ten year history.
The goal of the competition is to help ease the transition from research laboratory to market. Swiftsure Innovations will receive a prize package that includes $25,000 in seed funding and an advisory services package worth more than $30,000. Swiftsure Innovations was up against AffinityImmuno Inc. from Prince Edward Island, and 3D BioFibR from Nova Scotia.
“This year’s competition highlights the strong leadership and innovation coming from health and life sciences startups in the region and the need for continued support programs like the BioInnovation Challenge.” Scott Moffitt, Executive Director, BioNova
The Judging Panel: Rhiannon Davies – Founding and Managing Partner, Sandpiper Ventures Arif Aziz, PhD – Senior Manager, National Life Science SR&ED, MNP Patricia Folkins – Partner, Bereskin & Parr LLP
BioNova leads the Health and Life Sciences sector in Nova Scotia and is the host of the BioPort Conference, the BioInnovation Challenge and BIC Junior. Our industry-led sector growth plan, BioFuture 2030, has made us the fastest growing sector in Atlantic Canada. We represent over 150 companies in Nova Scotia who have raised over $73 million in investment dollars since the beginning of 2020. Visit our website at www.BioNova.ca
BioPort provides a forum to educate, inform and inspire the health and life sciences community to develop their ideas, commercialize their technologies and build links within the region and with guests brought in from the U.S. and from around the world. For more information visit www.bioportatlantic.ca.
Shana Cristoferi, Marketing Manager, BioNova
902-830-9193 [email protected]
Four Atlantic Canadian medtech companies will present their cancer care solutions virtually during the first Health Challenge Pitch Event on Friday, June 19 at 12pm. In partnership with Nova Scotia Health Authority, Atlantic Canada Opportunities Agency, QEII Foundation, and BioNova, one medical technology company working to enhance cancer care will receive $100,000 and their technology will be considered for adoption by the NSHA.
This event is the first of five virtual pitch competitions focusing on health innovation, with topics differing at each event to focus on a health priority identified by the Nova Scotia Health Authority. The competition was created to drive innovation in the medtech space and encourage the adoption of technologies that exist to improve the accuracy and level of care medical practitioners require to make concise, life-saving diagnoses and treatments for patients in Atlantic Canada.
The four companies that will be pitching virtually on Friday, June 19 include:
● Picomole Inc.
● DMF Medical Inc.
● Adaptiiv Medical Technologies Inc.
Pitches will be 10 minutes in length, followed by five minutes for the judges to ask questions. The event is taking place via videoconference and begins at 12pm on Friday, June 19.
Those interested in watching are encouraged to register for the event on Eventbrite. Upcoming pitch topics will be announced in the coming weeks on our social media channels and website.
“The Health Innovation Challenge is meant to stimulate not only greater collaboration and engagement with our medtech partners, but to encourage those of us in the health system to problem solve in a different way. This competition represents a change in our approach to how we view partnerships in our health care system and health innovation.” – Dr. Gail Tomblin Murphy, Vice President, Research, Innovation & Discovery and CNE, Nova Scotia Health Authority
“BioNova has provided early support and leadership to all of the finalist companies which has accelerated their growth, making them strong candidates for the Health Challenge.” – Scott Moffitt, Executive Director, BioNova
“The QEII Foundation has a long-standing history of supporting cancer care priorities at the QEII – funding lifesaving clinics, equipment, treatment advancements and research. It is exciting to be part of finding innovative solutions to cancer care treatments for patients who need it most.” – Bill Bean, President and CEO, QEII Foundation
“Cancer is a disease that impacts so many of us, and it is inspiring to see strong leadership and innovation in cancer research from Atlantic Canadian medtech companies. I am confident these companies will continue to have a positive impact on patient care across our region.” – Martha Casey, Volta Interim CEO, and COO
Halifax, NS – November 8, 2018 – Today Picomole from Moncton, New Brunswick was named the winner of BioNova’s eighth annual BioInnovation Challenge (BIC) business pitch competition at BioPort 2018. Picomole is an innovative medical technology company with the goal of developing their patented and patent-pending technologies for breath analytics into the standard of care for non-invasive clinical diagnostics and personalized medicine.
Stephen Graham of Picomole said, “This experience has been invaluable. The mentorship and training we’ve received through this process has helped take Picomole to the next level, and we know the funding and the advisory services will help to elevate us even more.”
Atlantic Canada’s best health and life science innovators participate in the BioInnovation Challenge (BIC) business pitch competition each year. The competition’s goal is to help ease the transition from research laboratory to market. Picomole will receive a prize package that includes $25,000 in seed funding and an advisory services package worth more than $30,000. Picomole was up against Matthew Kay, CEO ofTalem Health Analytics and Gabrielle Masone, CEO of Coloursmith Labs.
“Our panel of judges had a difficult time selecting a winner because all seven finalists have what it takes to make their start up a success,” said Scott Moffitt, Executive Director of BioNova. “Congratulations to Picomole.”
The Judging Panel:
Jennifer Hamilton, Senior Director, New Ventures (Canada), Johnson & Johnson Innovation
Gerry Lacroix, Technology Sector Leader – Nova Scotia, Grant Thornton LLP
John Holyoake, Managing Director, Investment Banking, Bloom Burton & Co.
Shana Cristoferi, Marketing Manager, BioNova
Mobile: (902) 830-9193
[email protected]About BioNova
BioNova leads, accelerates, and advocates for Nova Scotia’s growing health and life sciences sector. Since 1993, BioNova has been accelerating the growth of its member companies. By hosting networking and educational events, and providing connections to potential funders and business resources, BioNova helps companies succeed. While these companies commercialize life-changing research to improve healthcare, provide healthier food, and develop sustainable solutions, BioNova advocates on behalf of the sector. BioNova champions the sector’s cluster of world-class research facilities, incubator programs, and companies who, together, bring investment and jobs to Nova Scotia. www.bionova.caAbout BioPort 2018
The 17th annual BioPort conference will take place at the Halifax Convention Centre on November 7-8, 2018. BioPort provides a forum to educate, inform and inspire the health and life sciences community to develop their ideas, commercialize their technologies and build links within the region and with guests brought in from the U.S. and from around the world. www.bioportatlantic.ca]]>
BioPort 2018 Announces Keynote Speakers
And Explores the Future of Life Sciences in Atlantic CanadaJune 21, 2018 – Halifax, NOVA SCOTIA – Health and life sciences innovators, industry leaders, and investors from across North America will come together to attend BioPort 2018, on November 7-8, 2018 at the Halifax Convention Centre. This year’s event will feature keynote speakers Dr. Corrina Lathan, CEO of AnthroTronix, Inc. and William Charnetski, Ontario’s Chief Health Innovation Strategist, who will explore the transformative impact of technology on life sciences companies and health care. The annual event will also feature a business pitch competition and an exciting new program targeting Nova Scotia’s youth.
“BioPort highlights the potential of the health and life sciences sector in Atlantic Canada to tackle the world’s toughest challenges,” said Scott Moffitt, Managing Director of BioNova. “This year our speakers will share how embracing disruptive technologies like robotics, artificial intelligence, and synthetic biology, present opportunities to grow our sector.”
Corinna Lathan, Ph.D., will provide the keynote address on November 7, 2018 at 6:00 pm ADT. Dr. Lathan is a neuroscientist, engineer, and health technology entrepreneur. Her company has successfully developed an FDA-cleared mobile platform for healthcare providers to assess cognitive function. She has also developed robotics for kids with disabilities, and wearable sensors for training surgeons and soldiers. These human-technology innovations have been featured in Forbes and Time magazines, and led to Dr. Lathan being named as MIT Technology Review Magazine’s ‘Top 100 World Innovators’.
On November 8, 2018 at 12:30 pm ADT, William Charnetski, LL.B, will provide a keynote address on how collaboration across the health care system facilitates the adoption of innovative health technologies. Mr. Charnetski is an accomplished national and global executive who has worked in the highest levels of business, law, and government. For over 10 years he was vice president and general counsel for AstraZeneca. He was also a partner at the law firm Torys LLP and served as chief of staff to The Hon. William Graham, P.C., Q.C.
As per previous years, BioPort will feature the BioInnovation Challenge (BIC), an Atlantic Canadian health and life science business pitch competition that gives entrepreneurs a chance to win $25,000 in funding to develop their business idea. New to this year’s program, the conference will also feature BioInnovation Challenge Junior (BIC Junior), for Nova Scotian high school and first year post-secondary students to create health and life science business ideas. The winner will receive a prize of $2,000.
For more information or to register for the event, visit BioPortAtlantic.ca. Complimentary media registration is available to reporters. Follow #BioPort2018 @BioNovaNS for updates.
Since 2002, BioPort has provided a forum to inform and inspire the health and life sciences community to develop their ideas, commercialize their technologies, and build links within the region, nationally and abroad.
About BioNovaBioNova leads, accelerates, and advocates for Nova Scotia’s growing health and life sciences sector. Since 1993, BioNova has been accelerating the growth of its member companies. By hosting networking and educational events, and providing connections to potential funders and business resources, BioNova helps companies succeed. While these companies commercialize life-changing research to improve healthcare, provide healthier food, and develop clean energy solutions, BioNova advocates on behalf of the sector. BioNova champions the sector’s cluster of world-class research facilities, incubator programs, and companies who, together, bring investment and jobs to Nova Scotia.
For more Information, contact:
Marketing Manager, BioNova
The keynote speakers for the 2018 BioPort conference will be Corrina Lathan, CEO of AnthroTronix in Maryland, and William Charnetski, Ontario’s Chief Health Innovation Strategist.BioNova, which organizes the annual gathering for life science innovators, industry leaders, and investors from across North America, revealed the keynote speakers in a statement last week. BioPort will take place at the Halifax Convention Centre on Nov. 7 and 8.
“BioPort highlights the potential of the health and life sciences sector in Atlantic Canada to tackle the world’s toughest challenges,” said Scott Moffitt, Managing Director of BioNova, in the statement.
“This year our speakers will share how embracing disruptive technologies like robotics, artificial intelligence, and synthetic biology, present opportunities to grow our sector.”
Lathan will give her keynote address the evening of Nov. 7 and Charnetski will give his on Nov. 8 in the afternoon. Their talks will dive into the relationship between technology and life sciences companies and health care systems.
Lathan’s company provides healthcare providers with a mobile platform to moniter cognitive function. In her career she has also developed robotics for kids with disabilities, and wearable sensors for training surgeons and soldiers.
Charnetski, a global executive who has worked in the highest levels of business, law, and government, will discuss how collaboration across the healthcare system requires the adoption of innovative health technologies.
Since 2011, BioPort has been hosting the BioInnovation Challenge, a pitching competition open to health and life science entrepreneurs from the East Coast. This year, participants could win up to $25,000 in funding to develop their business idea.
Past winners include, Pfera from Fredericton, MacKenzie Healthcare Technologies and Covina Biomedical, both of which are from Nova Scotia.
Pfera, a company that is developing products for safer and more cost-effective horse breeding, won in October 2017 and was able to start conductng clinical trials two months later.
The company, which helps breeders determine the due date of a pregnant mare, was incorporated in January 2017 and aims to launch late this year.
BioPort 2018 is also the inaugural year for a new program for Nova Scotia’s youth.
BioInnovation Challenge Junior (BIC Junior) is open to Nova Scotian high school and first year post-secondary students with health and life science business ideas. The winner will receive a prize of $2,000.
You can register for the events here.
See original post here
By Peter Moreira
For the past few years Kami Harris has received 1,000 ticks annually at her office at Mount Allison University in Sackville, N.B. She hopes it continues. Her business model depends on it.
Some come from scientists, some from New Brunswick’s Natural Resources Department, others from members of the public who have heard about her work in ticks and Lyme disease.
Harris is the founder and CEO of Zecken Laboratories, which is dedicated to enhancing the diagnosis of Lyme disease. She has been studying ticks and Lyme disease for her PhD at Mount A, and now she is transforming her research into a company. Her faith in the endeavour is based in part on the growing public awareness and fear of Lyme disease.
“We’ve gone in five years from people thinking, ‘This could happen in the Maritimes’ to ‘This is a big problem,’” Harris told the BioPort Atlantic conference in Halifax last week. “Half my day already goes to answering emails from people who know I’m the ‘tick girl.’”
Lyme disease is a bacterial infection spread to humans by blood-feeding insects, particularly deer ticks. And as the climate warms, ticks are spreading north and their bites are becoming more common in the Maritimes. Concern about Lyme disease is growing.
Harris said there are actually 21 types of Lyme disease but current diagnostic tests only identify one type. That means about 90 per cent of the instances of Lyme disease go undetected, which can lead to long-term health problems. What Zecken is doing is devising products that can identify markers in the other types of Lyme disease to improve diagnosis and therefore generate more treatment.
The company has already identified peptides that show the presence of the affliction, and continues to research the disease to identify new strains as they come along.
“We’re not only going to give you the right information; we’ll give you more information,” Harris said. “We’ll be able to tell you the type of Lyme disease you have.”
At BioPort, Zecken was a finalist in the BioInnovation Challenge, the region’s main pitching competition for life sciences competitions. Earlier this year, it was a semifinalist in Breakthru, the main startup competition in New Brunswick. Soon it will be ready to start bringing in revenue.
The company is planning a basic swab test for consumers in 2018. For $50, consumers can swab their mouths at home, send the sample to the company and learn if they have Lyme disease and if so what type. Harris said this service will not require regulatory approval.
The swab service will bring in revenues as the company seeks regulatory clearance for more sophisticated products, such as a blood test to detect Lyme disease for health-care providers. It also wants a business-to-business product to offer to such industries as forestry, where tick bites are a growing concern.
So far, the company’s research has been financed through Harris’ research funding, but she and her three teammates know they will need a more structured financing model.
They will probably aim for a $250,000 funding round in their first year.]]>